Even in T2DM patients undergoing insulin therapy, an oral hypoglycemic agent is also commonly administered, and dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently used partner for insulin therapy in daily clinical practice in Japan [9]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.